Application of MFAP5 in preparing preparation for screening markers of people sensitive to alpha interferon intervention in liver cancer

Abstract

The invention belongs to the technical field of clinical detection of biomedicine, and particularly relates to an application of MFAP5 in preparing a preparation of the screening markers for people sensitive to alpha interferon intervention in liver cancer. The method comprises the steps: detecting and analyzing tissue samples of interferon intervention and non-intervention liver cancer patients through adopting an RNA-seq high-throughput expression profile sequencing method; screening out the secretory protein MFAP5 with expression difference; performing the identification through immunohistochemistry with the three methods of immunohistochemistry, Western blot and ELISA, so as to prove that the MFAP5 secreted protein has significant expression difference in interferon intervention and non-intervened human liver cancer tissue. Meanwhile, the obvious expression difference exists in human peripheral venous blood, and the MFAP5 is a key molecule in the interferon intervention liver cancer process, can be used as a marker for screening interferon intervention liver cancer sensitive people and is further used for screening interferon intervention liver cancer sensitive people, and theaccuracy is high.

Description

technical field [0001] The invention belongs to the technical field of biomedical clinical detection, relates to the new medical application of MFAP5 protein, and specifically relates to the use of MFAP5 protein as a detection marker in the preparation of preparations for screening alpha interferon intervention liver cancer sensitive groups. Background technique [0002] The information disclosed that primary liver cancer (Hepatocellular carcinoma, HCC) ranks sixth in the incidence of malignant tumors in the world and the second in mortality, and is the second leading cause of cancer death in my country. After decades of hard work, my country's liver cancer research has made significant progress, but the 5-year metastasis and recurrence rate after radical resection is still greater than 60%. Postoperative recurrence and metastasis is still the main obstacle to further improve the prognosis of patients with liver cancer. So far, there are few drugs that can effectively inhib...

AI Technical Summary

Problems solved by technology

Among many anticancer drugs, interferon-α is one of the few effective drugs for liver cancer, which has great clinical application value; studies have shown that different tumor-bearing individuals have different drug sensitivities, which leads to the effect of interferon-α on liver cancer patients. The overall curative effect cannot fully meet the clinical requirements at present, and the industry believes that whether its curative effect can be further improved mainly depends on finding effective molecular markers for identifying sensitive groups

[0004] The prior art discloses that MFAP5 is a multifunctional protein that plays an important role in elastic microfibril assembly and regulation of endothelial cell behavior and is considered as a novel regulator of cell survival, however the role of MFAP5 in cancer remains to be elucidated

Interferon-alpha has been widely used in the clinical anti-hepatocellular carcinoma metastasis and recurrence treatment. However, so far, there has been no report on MFAP5 as a marker for screening interferon-alpha intervening in sensitive populations of liver cancer.

Images